Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Klein, I. H.H.T.
Right arrow Articles by Blankestijn, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Klein, I. H.H.T.
Right arrow Articles by Blankestijn, P. J.
J Am Soc Nephrol 14:3239-3244, 2003
© 2003 American Society of Nephrology

CLINICAL SCIENCE

Sympathetic Nerve Activity Is Inappropriately Increased in Chronic Renal Disease

Inge H.H.T. Klein*, Gerry Ligtenberg*, Jutta Neumann*, P. Liam Oey{dagger}, Hein A. Koomans* and Peter J. Blankestijn*

Departments of *Nephrology and {dagger}Clinical Neurophysiology, University Medical Center Utrecht, The Netherlands

Correspondence to Dr. Peter J. Blankestijn, Department of Nephrology, Room F03.226, University Medical Center, P.O. Box 85500, 3508 GA Utrecht, The Netherlands. Phone: +31-30-2507336; Fax: +31-30-2543492; E-mail: p.j.blankestijn{at}azu.nl


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
ABSTRACT. The hypothesis that in hypertensive patients with renal parenchymal disease sympathetic activity is "inappropriately" elevated and that this overactivity is a feature of renal disease and not of a reduced number of nephrons per se is addressed. Fifty seven patients with renal disease (various causes, no diabetes, all on antihypertensive medication) were studied, age range 18 to 62, creatinine clearance 10 to 114 ml/min per 1.73 m2. Antihypertensives were stopped, but diuretics were allowed, to prevent overhydration. Matched control subjects were also studied. The effect of changes in fluid status was examined in seven patients while on and after stopping diuretics and in eight control subjects while on low- and high-sodium diet. Seven kidney donors were studied before and after unilateral nephrectomy. Sympathetic activity was quantified as muscle sympathetic nerve activity (MSNA) in the peroneal nerve. Mean arterial pressure, MSNA, and plasma renin activity were higher in patients than in control subjects, respectively (115 ± 12 and 88 ± 11 mmHg, 31 ± 15 and 18 ± 10 bursts/min, and 500 [20 to 6940] and 220 [40 to 980] fmol/L per s; P < 0.01 for all items). Extracellular fluid volume (bromide distribution) did not differ. Seven patients were studied again after stopping diuretics. MSNA decreased from 34 ± 18 to 19 ± 18 bursts/min (P < 0.01). Eight healthy subjects were studied during low- and high-sodium diet. MSNA was 26 ± 12 and 13 ± 7 bursts/min (P < 0.01). The curves relating extracellular fluid volume to MSNA were parallel in the two groups but shifted to a higher level of MSNA in the patients. In the kidney donors, creatinine clearance reduced by 25%, but MSNA was identical before and after donation. It is concluded that in hypertensive patients with renal parenchymal disease, sympathetic activity is inappropriately high for the volume status and that reduction of nephron number in itself does not influence sympathetic activity.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Hypertension is common in chronic renal disease. Its prevalence varies between 30 and 100% depending on the target population, cause of renal disease, and level of renal function (1,2). Volume overload and activation of the renin system have long been recognized as main pathogenetic players.

There is some indication that sympathetic nervous activity is also involved. Experimental data have indicated that the presence of parenchymal injury results in neurogenic hypertension (3).Muscle sympathetic nerve activity (MSNA) is increased in both dialysis and predialysis patients, whereas bilaterally nephrectomized patients have MSNA identical to control subjects (4–6). Recently, we reported that MSNA is increased in hypertensive patients with polycystic kidney disease and still normal kidney function (7). Thus, the available data indicate that renal parenchymal changes can cause sympathetic hyperactivity. Sympathetic activity increases with age (7–9) and is feedback-regulated by baroreflex control and volume status (10). In patients with chronic renal disease, volume status may vary substantially. Therefore, it is critical that this be taken into account when assessing sympathetic activity in individual patients.

The overall hypothesis for the present studies was that sympathetic activity is "inappropriately" increased in patients with renal parenchymal disease. In view of the above mentioned, the specific aims were (1) to establish that sympathetic activity is increased in relation to the volume status of these patients and (2) to establish that sympathetic hyperactivity is a feature of chronic renal disease and not of reduced number of nephrons but intact parenchymal structure.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Subjects
Patients with hypertension (i.e., using antihypertensive drugs and/or BP >140/90 mmHg when off medication) and with chronic renal disease (creatinine clearance >10 ml/min and stable in the last 3 mo) could enter the study. Patients with clinically manifest heart disease (congestive heart failure, ischemic heart disease, or atrial fibrillation) or diabetes or patients who were on steroids were excluded. Renal disease was diagnosed by ultrasound studies (in case of polycystic kidney disease), intravenous urograms, or kidney biopsy. Healthy control subjects were matched for age, gender, and body mass index. Kidney donors were studied before and after unilateral nephrectomy. The kidney donors had normal BP without medication, normal plasma creatinine (<110 µmol/L), and no proteinuria.

Fifty-seven patients (polycystic kidney disease, n = 31; IgA nephropathy, n = 5; obstructive uropathy disease, n = 5; chronic pyelonephritis, n = 2; nephrosclerosis, n = 3; focal sclerosis, n = 1; mesangial proliferative glomerulonephritis, n = 1; interstitial nephritis, n = 2; analgesic nephropathy, n = 2; Alport syndrome, n = 2; or unknown, n = 3), 57 control subjects, and seven kidney donors were studied.

Protocol
The institutional committee for studies in humans approved the protocol. All subjects gave their written informed consent. Patients were studied when taken off antihypertensive medication for at least 2 wk. Diuretics were continued to maintain normovolemia in 26 of the 57 patients but were not taken on the study day. Vitamin D supplements, phosphate binders, and/or HMG-CoA-reductase inhibitors were continued as well.

A subgroup of seven patients was studied twice, when clinically normovolemic (i.e., no clinical signs of fluid overload) and when taken off diuretics for >7 d. During both study sessions, patients were without angiotensin-converting enzyme (ACE) inhibition or angiotensin II antagonist. An additional group of eight control subjects were studied twice as well, while on high-salt diet (regular diet + salt supplements: 200 mmol/d for 5 d) and while on low-salt diet (30 mmol/d for 5 d, and frusemide, 20 mg twice daily, during the first 2 d). The order of the investigations regarding changes in volume status was randomized. Fluid status was assessed by extracellular volume (ECV) measurements (see below). Seven living kidney donors were investigated shortly before (2 to 12 wk) and after (12 to 58 wk) unilateral nephrectomy.

All subjects underwent an identical set of measurements, in supine position in a quiet room with an ambient temperature of 22 to 24°C. The protocol, which is described in more detail previously (5,7), included measurement of supine BP, heart rate, MSNA, baroreflex sensitivity, ECV. and plasma renin activity (PRA). On the day before the MSNA measurement, subjects collected 24-h urine.

BP and heart rate were measured in a recumbent position with a standard mercury sphygmomanometer; means of three measurements are presented. During the baroreceptor sensitivity assessments, BP and heart rate were recorded continuously by finger plethysmography (11). MSNA was recorded with a unipolar tungsten microelectrode placed in a muscle nerve fascicle of the peroneal nerve (6,7,12). Success rate of obtaining an adequate neural signal is approximately 85%. The interbeat intervals were measured from the ECG. From the interbeat interval, the heart rate is computed. An intravenous cannula for infusion and blood sample collection was inserted into an antecubital vein. After instrumentation, the subjects rested for 20 min. Baseline measurements for BP, heart rate, and MSNA were obtained, and blood was sampled for PRA and bromide. Next, the arterial baroreflex sensitivity was assessed as the response of MSNA and of heart rate to changes in BP induced by subsequent continuous infusion of sodium nitroprusside and phenylephrine (5,7). Bromide distribution volume was used as an index of ECV (13). Plasma bromide levels range between 1 and 3 mmol/L, which is well below the therapeutic and toxic levels. Normalization for lean body mass allows comparison between men and women (14). The normal range in our laboratory is 273 to 334 ml/kg lean body mass. PRA was measured by RIA (15).

Data Analysis
Data are mean ± SD, unless indicated otherwise. MSNA was expressed as the number of bursts of sympathetic activity per minute or as the number of bursts per 100 heart beats to correct for differences in heart rate. Intraobserver and interobserver reproducibility are 4.5 ± 0.5% and 6.2 ± 0.7%. Baroreflex sensitivity is quantified as described elsewhere (5,7).

Statistical Analyses
PRA was analyzed after logarithmic transformation. Baseline characteristics of patients and control subjects were compared by unpaired t test. Only independent variables were included in the regression analysis. Analysis of covariance was used to calculate differences between slopes when appropriate. Pearson correlation coefficients were calculated followed by stepwise linear regression when appropriate. P < 0.05 was considered to be statistically significant.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
All patients were on antihypertensive drugs (always including an ACE inhibitor or angiotensin II antagonist), in 26 cases combined with diuretics. Their office BP (in sitting position using mercury sphygmomanometer) was 137/84 mmHg (±11/8). After stopping the antihypertensive medication, BP increased in all patients but no patient became severely hypertensive (diastolic BP >120 mmHg).

Patients and control subjects were matched for age, gender, and body mass index. Creatinine clearance in patients was lower and ranged from 10 to 118 ml/min. Despite that ECV did not differ between the two groups, BP, MSNA, and PRA were markedly higher in the patients (all <0.001; Table 1). BP did not correlate with MSNA. Baroreceptor sensitivity was not different between patients and control subjects (Table 1).


View this table:
[in this window]
[in a new window]

  		Table 1. Baseline characteristics of chronic renal disease patients and control subjectsa
 
In patients, correlations existed between age and creatinine clearance (r = -0.59; P < 0.001) and age and MSNA (r = 0.62; P < 0.001), between creatinine clearance and mean arterial pressure (r = -0.31; P < 0.05), and between MSNA and log PRA (r = 0.29; P < 0.05). In control subjects, age correlated with creatinine clearance (r = -0.65; P < 0.001), MSNA (r = 0.69; P < 0.001), and log PRA (r = -0.36; P < 0.05), and a correlation existed between mean arterial pressure and log PRA (r = -0.44; P < 0.05). Multiple regression analysis revealed age and PRA as predictive for MSNA in patients (MSNA = -9.3 + 0.86 x age + 0.004 x PRA; r2 = 0.48; P < 0.001). In control subjects, age predicted MSNA (MSNA = 2.6 + 0.39 x age; r2 = 0.37; P < 0.001). The regression line for age and MSNA was steeper in patients compared with control subjects (P < 0.01).

Effects of Changes in Fluid Status
Seven patients (diagnosis: nephrosclerosis (n = 2), polycystic kidney disease (n = 2), Alport disease (n = 2), and chronic pyelonephritis (n = 1); age: 49 ± 7 yr; four men; creatinine clearance: 39 ± 18 ml/min) were examined twice, while clinically normovolemic and after stopping diuretic therapy. After stopping the diuretics, body weight increased by 1.6 ± 0.6 kg. ECV and BP increased, and MSNA and PRA were significantly suppressed in the hypervolemic compared with the normovolemic condition (Table 2, Figure 1).


View this table:
[in this window]
[in a new window]

  		Table 2. Characteristics of patients (n = 7) in normovolemic and hypervolemic statea
 


View larger version (17K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Figure 1. Plots of ECV and MSNA and extracellular volume and plasma renin activity in patients with chronic renal failure (•) in normovolemic and hypervolemic condition and in healthy volunteers ({circ}) during low- and high-sodium diet.

 
Eight control subjects (age: 34 ± 15 yr; four women) were measured while on a low-sodium diet and a high-sodium diet. Dietary compliance was good, evidenced by the urinary sodium output. These manipulations resulted in changes in body weight comparable to those in the patients. Again, an increase in ECV coincided with a suppression of MSNA and PRA (Table 3, Figure 1).


View this table:
[in this window]
[in a new window]

  		Table 3. Characteristics of control subjects (n = 8) during low- and high-sodium diet a
 
Plots of MSNA versus ECV in patients and control subjects showed parallel curves, but for patients, it was shifted to a higher level of sympathetic activity. The MSNA levels corresponding to the low and high ECV were significantly higher than in control subjects (P < 0.01 and P < 0.05 respectively; Figure 1). Plots of PRA versus ECV revealed a similar pattern. Baroreceptor sensitivity was not different between the different conditions or between patients and control subjects.

Kidney Donors
Creatinine clearance decreased, but BP, PRA, and MSNA remained unchanged (Table 4).


View this table:
[in this window]
[in a new window]

  		Table 4. Characteristics of kidney donors (n = 7) before and after nephrectomya
 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
To our knowledge, this is the first study that shows that the relation between short-term changes in sympathetic activity, quantified as MSNA, and volume parallels that in healthy subjects but is shifted to a higher level of MSNA. The data give further support to our previous findings that MSNA, which represents the sympathetic activity to the resistance vessels, is increased in normovolemic hypertensive patients with renal parenchymal disease studied in steady state (5,7). MSNA does not change significantly after unilateral nephrectomy in healthy kidney donors.

Fluid overload is considered to play a major role in the pathogenesis of nephrogenic hypertension. It has long been recognized that the renin-angiotensin system is "inappropriately" activated in relation to the fluid status (16). This contributes to the hypertension and explains why hypertension may persist even after correction of the fluid overload. The role of the sympathetic nervous system in renal hypertension is less clear. Whereas the renin system is especially involved in the long-term regulation of BP, the sympathetic nervous system is particularly relevant for the short-term regulation. This is apparent from the quick baroreflex-mediated changes in sympathetic activity, confirmed also in the present study. Arterial baroreceptor sensitivity in patients—i.e., the ability of the sympathetic nervous system to respond to acute changes in BP—was not different from control subjects. Changes in volume status have a reciprocal effect on plasma noradrenaline (17) and, as is shown in our study, on MSNA. MSNA is also suppressed in subjects with mineralocorticoid excess (18). However, in clinical situations with sustained low BP, such as heart failure, resting sympathetic activity is elevated (19). A recent study showed that MSNA remained consistently elevated over 8 wk in hypertensive subjects who switched to a low-salt diet (20). Clearly, changes in volume status and BP have a sustained effect on sympathetic activity.

The present study shows that resting sympathetic activity is, on average, elevated in hypertensive patients with renal parenchymal disease compared with control subjects. The physiologic increase with age is still present (8,9). Although the number of studied subjects was limited, the present data clearly show that changes in the volume status induced comparable changes in sympathetic activity as observed in the healthy subjects, however, at a higher level of sympathetic activity. Therefore, we conclude that in hypertensive patients with renal parenchymal disease, sympathetic activity is inappropriately high for the volume status, similar as has been described for the activity of the renin angiotensin system (16). Animal experiments have shown that intrarenal ischemia by arterial constriction (21) or by intrarenal phenol injection can cause sympathetic activation by stimulation of renal afferents (4). That indeed the diseased kidney induces the sympathetic activation is confirmed by the observation that sympathetic activity is not increased in patients who underwent bilateral nephrectomy because of hypertensive end-stage renal disease (5). Our hypothesis is that renal parenchymal disease, by causing local or diffuse compromised perfusion, leads to stimulation of both the renin angiotensin system and the sympathetic nervous system. This suggests that not the renal failure itself but the renal structural changes are crucial. Indeed, we have shown that hypertensive subjects with adult polycystic kidney disease show increased MSNA before developing loss of GFR (7). In the present study, we found no independent correlation between the severity of renal failure and sympathetic activity. We also observed that unilateral nephrectomy does not increase MSNA. Even though this was based on a few subjects, it seems that a major reduction in the number of functioning nephrons without damage to the residual parenchyma will by itself not induce significant sympathetic activation.

The relation between PRA and MSNA may indicate a cause–effect relation or a common origin. Angiotensin II can increase central sympathetic output (22). Renal ischemia will stimulate the renin-angiotensin system. Indeed, the patients of this study had increased PRA. Previously, we demonstrated that an ACE inhibitor and an angiotensin II receptor antagonist reduce sympathetic overactivity, strongly suggesting that angiotensin II importantly contributes in the pathogenesis of the sympathetic hyperactivity (5,23).

The present study was limited to hypertensive patients with renal parenchymal disease, starting from the idea that it is in these patients that renin activity is increased (16). In these patients, sympathetic activity is apparently also high. We have shown that MSNA is normal in normotensive patients with polycystic kidney disease (7). It remains unclear whether sympathetic activity is lower or normal in normotensive patients with other types of renal disease. Furthermore, many of the present subjects had polycystic kidney disease, a condition associated with pronounced parenchymal structural changes. The numbers of patients with other conditions are too small to allow separate evaluation of the data.

In conclusion, the present large study shows definitely that sympathetic activity is increased in hypertensive patients with renal parenchymal disease. Sympathetic activity is inappropriately increased for the volume status. It is not increased in subjects with a reduced number of nephrons in the absence of renal parenchymal disease. Recent evidence indicates that sympathetic activity is associated with mortality and cardiovascular outcomes in patients with chronic renal failure (24). Although not specifically addressed by this study, we suggest that normalization of sympathetic overactivity should be considered a specific goal of treatment of hypertensive patients with renal parenchymal disease.


   Acknowledgments
 
I.H.H.T.K. and J.N. were supported by grants of the Dutch Kidney Foundation (C97-1684 and KC 24).


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Levey AS, Beta JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, Klag MJ, Mailloux LU, Manske CL, Meyer KB, Parfrey PS, Pfeffer MA, Wenger NK, Wilson PW, Wright JT: Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? Am J Kidney Dis 32: 853–906, 1998[Medline]
  2. KDOQI Clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Am J Kidney Dis 39 (Suppl 1): S1–S266, 2002[CrossRef][Medline]
  3. Ye S, Ozgur B, Campese VM: Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. Kidney Int 51: 722–727, 1997[Medline]
  4. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG: Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 327: 1912–1918, 1992[Abstract]
  5. Ligtenberg G, Blankestijn PJ, Oey PL, Klein IH, Dijkhorst-Oey LT, Boomsma F, Wieneke G, van Huffelen AC, Koomans HA: Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 340: 1321–1328, 1999[Abstract/Free Full Text]
  6. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, Dietl KH, Rahn KH: Sympathetic nerve activity in end-stage renal disease. Circulation 106: 1974–1979, 2002[Abstract/Free Full Text]
  7. Klein IHHT, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 12: 2427–2433, 2001[Abstract/Free Full Text]
  8. Ebert TJ, Morgan BJ, Barney JA, Denahan T, Smith JJ: Effects of aging on baroreflex regulation of sympathetic activity in humans. Am J Physiol 263: H798–H803, 1992
  9. Davy KP, Tanaka H, Andros EA, Gerber JG, Seals DR: Influence of age on arterial baroreflex inhibition of sympathetic nerve activity in healthy adult humans. Am J Physiol 275: H1768–H1772, 1998
  10. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Bolla G, Mancia G: Baroreflex impairment by low sodium diet in mild or moderate essential hypertension. Hypertension 29: 802–807, 1997[Abstract/Free Full Text]
  11. Bos WJ, Imholz BP, van Goudoever J, Wesseling KH, van Montfrans GA: The reliability of noninvasive continuous finger blood pressure measurement in patients with both hypertension and vascular disease. Am J Hypertens 5: 529–535, 1992[Medline]
  12. Wallin BG, Sundlof G: A quantitative study of muscle nerve sympathetic activity in resting normotensive and hypertensive subjects. Hypertension 1: 67–77, 1979[Abstract/Free Full Text]
  13. Snel YE, Brummer RJ, Bol E, Doerga ME, Zelissen PM, Zonderland ML, Boer P, Koomans HA, Koppeschaar HP: Direct assessment of extracellular water volume by the bromide-dilution method in growth hormone-deficient adults. Eur J Clin Invest 25: 708–714, 1995[Medline]
  14. Boer P: Estimated lean body mass as an index for normalization of body fluid volumes in humans. Am J Physiol 247: F632–F636, 1984
  15. Boer P, Sleumer JH, Spriensma M: Confirmation of the optimal pH for measuring renin activity in plasma. Clin Chem 31: 149–150, 1985[Free Full Text]
  16. Schalekamp MA, Beevers DG, Briggs JD, Brown JJ, Davies DL, Fraser R, Lever AF, Medina A, Morton JJ, Robertson JI, Tree M: Hypertension in chronic renal failure. Am J Med 55: 379–390, 1973[CrossRef][Medline]
  17. Roos JC, Koomans HA, Dorhout Mees EJ, Delawi IMK: Renal sodium handling in normal humans subjected to low, normal, and extremely high sodium supplies. Am J Physiol 249: F941–F947, 1985
  18. Miyajima E, Yamada Y, Yoshida Y, Matsukawa T, Shionori H, Tochikubo O, Ishii M: Muscle sympathetic nerve activity in renovascular hypertension and primary aldosteronism. Hypertension 17: 1057–1062, 1991[Abstract/Free Full Text]
  19. Grassi G, Seravalle G, Cattaneo BM, Lanfranchi A, Vailati S, Giannattasio C, Del Bo A, Sala C, Bolla GB, Pozzi M, Mancia G: Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circulation 92: 3206–3211, 1995[Abstract/Free Full Text]
  20. Grassi G, DellÓro R, Seravalle G, Foglia G, Trevano FQ, Mancia G: Short- and long-term neuroadrenergic effects of moderate dietary sodium restriction in essential hypertension. Circulation 106: 1957–1961, 2002[Abstract/Free Full Text]
  21. Faber JE, Brody MJ: Afferent renal nerve-dependent hypertension following acute renal artery stenosis in the conscious rat. Circ Res 57: 676–688, 1985[Abstract/Free Full Text]
  22. Reid IA: Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure [Editorial]. Am J Physiol 262: E763–E778, 1992
  23. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ: Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol 14: 425–430, 2003[Abstract/Free Full Text]
  24. Zoccali C, Mallamaci F, Parlengo S, Cutrupi S, Benedetto A, Tripepi G, Binanno G, Rapisardi F, Fatuzzo P, Seminara G, Cateliotti A, Stancanelli B, Malatino LS: Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 105: 1354–1359, 2002[Abstract/Free Full Text]
Received for publication July 1, 2003. Accepted for publication September 13, 2003.




This article has been cited by other articles:


Home page
 J. Appl. Physiol.Home page
J. Park, V. M. Campese, N. Nobakht, and H. R. Middlekauff
Differential distribution of muscle and skin sympathetic nerve activity in patients with end-stage renal disease
J Appl Physiol, December 1, 2008; 105(6): 1873 - 1876.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
G. Li, J. Xu, P. Wang, H. Velazquez, Y. Li, Y. Wu, and G. V. Desir
Catecholamines Regulate the Activity, Secretion, and Synthesis of Renalase
Circulation, March 11, 2008; 117(10): 1277 - 1282.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
M. B. Davidson, J. K. Hix, D. G. Vidt, and D. J. Brotman
Association of Impaired Diurnal Blood Pressure Variation With a Subsequent Decline in Glomerular Filtration Rate.
Arch Intern Med, April 24, 2006; 166(8): 846 - 852.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
K. C. Abbott, F. C. Trespalacios, L. Y. Agodoa, A. J. Taylor, and G. L. Bakris
{beta}-Blocker Use in Long-term Dialysis Patients: Association With Hospitalized Heart Failure and Mortality
Arch Intern Med, December 13, 2004; 164(22): 2465 - 2471.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
J. Neumann, G. Ligtenberg, L. Oey, H. A. Koomans, and P. J. Blankestijn
Moxonidine Normalizes Sympathetic Hyperactivity in Patients with Eprosartan-Treated Chronic Renal Failure
J. Am. Soc. Nephrol., November 1, 2004; 15(11): 2902 - 2907.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
P. J. Blankestijn
Sympathetic hyperactivity in chronic kidney disease
Nephrol. Dial. Transplant., June 1, 2004; 19(6): 1354 - 1357.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
J. P. Kooman, F. M. van der Sande, and K. M. L. Leunissen
Sodium, blood pressure and cardiovascular pathology: is it all volaemia?
Nephrol. Dial. Transplant., May 1, 2004; 19(5): 1046 - 1049.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
H. A. Koomans, P. J. Blankestijn, and J. A. Joles
Sympathetic Hyperactivity in Chronic Renal Failure: A Wake-up Call
J. Am. Soc. Nephrol., March 1, 2004; 15(3): 524 - 537.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Klein, I. H.H.T.
Right arrow Articles by Blankestijn, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Klein, I. H.H.T.
Right arrow Articles by Blankestijn, P. J.

HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP